Financial Insights Inc. bought a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) in the 2nd quarter, HoldingsChannel reports. The fund bought 250 shares of the biotechnology company’s stock, valued at approximately $44,000.
Several other large investors have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Axon Enterprise in the 2nd quarter worth about $1,220,167,000. Baillie Gifford & Co. bought a new stake in Axon Enterprise in the 2nd quarter worth about $800,752,000. Lord Abbett & CO. LLC bought a new stake in Axon Enterprise in the 2nd quarter worth about $248,663,000. Bank of New York Mellon Corp bought a new stake in Axon Enterprise in the 2nd quarter worth about $110,744,000. Finally, abrdn plc bought a new stake in Axon Enterprise in the 2nd quarter worth about $108,771,000. 75.32% of the stock is owned by institutional investors.
A number of research firms have weighed in on AXON. Raymond James boosted their target price on shares of Axon Enterprise from $200.00 to $223.00 and gave the company a “strong-buy” rating in a research note on Friday, August 6th. Robert W. Baird boosted their target price on shares of Axon Enterprise from $195.00 to $220.00 and gave the company an “outperform” rating in a research note on Friday, August 6th. Finally, Needham & Company LLC boosted their target price on shares of Axon Enterprise from $190.00 to $250.00 and gave the company a “buy” rating in a research note on Friday, August 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $204.50.
Shares of AXON stock traded down $1.35 during trading on Monday, reaching $171.03. 8,368 shares of the company’s stock traded hands, compared to its average volume of 473,503. The company has a market capitalization of $11.23 billion, a P/E ratio of -159.61 and a beta of 0.46. The firm’s 50-day moving average is $183.32 and its 200 day moving average is $160.73. Axon Enterprise, Inc. has a 1 year low of $80.54 and a 1 year high of $212.37.
Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Thursday, August 5th. The biotechnology company reported ($0.72) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.63). The business had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $173.07 million. Axon Enterprise had a negative net margin of 8.69% and a negative return on equity of 7.35%. Equities research analysts forecast that Axon Enterprise, Inc. will post -1.5 EPS for the current year.
About Axon Enterprise
Axon Enterprise, Inc engages in the development, manufacturing, and sale of conducted electrical weapons for personal defense. It operates through the TASER Weapons and Software and Sensors segments. The TASER Weapons segment sells conducted electrical weapons, accessories, and other related products and services.
Featured Article: How to Use a Moving Average for Trading
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.